Effectiveness of Hepatoprotectors in the Practice of a Family Doctor

##plugins.themes.bootstrap3.article.main##

Yevheniia Zaremba
Olha Smaliukh
Olha Zaremba

Abstract

Hepatoprotectors – drugs that form the basis of pathogenetic treatment of various liver diseases. They help restore impaired hepatocyte function, increase the resistance of liver cells to the effects of pathological factors, enhance the detoxification function of hepatocytes, have antioxidant properties. There is no generally accepted classification of hepatoprotectors today, they are divided into several groups depending on the origin: plant, animal, synthetic origin, products containing essential phospholipids, amino acids, vitamins, and other groups.


One of the well-known hepatoprotectors of plant origin is glycyrrhizin – the main active ingredient of licorice root. Licorice root (Glycyrrhiza glabra) is a drug used in medicine since ancient times, as evidenced by historical data from China, Japan, India, Greece, and Europe. Licorice root is widely used today in medicine and the food industry. Glycyrrhizin – potassium and calcium salt of glycyrrhizinic acid, has a wide range of properties. It is used mainly for the treatment of chronic liver disease. In non-alcoholic fatty liver disease, the use of glycyrrhizin helps reduce steatosis, inflammation in the liver has an antifibrotic effect. Studies on the use of glycyrrhizinic acid in hepatocellular carcinoma are actively conducted, as its antitumor properties are known. It is included in the treatment of chronic viral hepatitis. In vitro studies have shown the antiviral activity of glycyrrhizin against HIV-1, SARS-associated virus, respiratory syncytial virus, arboviruses, and its potential for coronavirus control is being discussed. Possibilities of application of glycyrrhizin and cardiovascular diseases are studied. In this article, we present a review of current literature data on glycerol, its properties, and applications in liver disease, other diseases, and our own clinical observations.

##plugins.themes.bootstrap3.article.details##

Section
Gastroenterology
Author Biographies

Yevheniia Zaremba, Danylo Halytsky Lviv National Medical University

Yevheniia H. Zaremba,

Department of Family Medicine at the Faculty of Postgraduate Education

Olha Smaliukh, Danylo Halytsky Lviv National Medical University

Olha V. Smaliukh,

Department of Family Medicine at the Faculty of Postgraduate Education

Olha Zaremba, Danylo Halytsky Lviv National Medical University

Olha V. Zaremba,

Department of Family Medicine at the Faculty of Postgraduate Education

References

Степанов Ю.М., Ягмур В.Б., Саленко А.В. Гліциризинова кислота: патофізіологічні аспекти формування фіброзу та ефективність у лікуванні захворювань печінки // Gastroenterologia. 2018;52(3):150–156. doi: 10.22141/2308-2097.52.3.2018.141846.

Харченко Н.В. В поиске идеального антифибротического препарата: как сказать “нет” фиброзу печени? Здоров’я України. 2017;24:1–7.

Хухліна О.С., Антонів А.А., Мандрик О.Є. Вплив гліциризину в комбінації з гліцином і метіоніном на стан компонентів позаклітинного матриксу та інтенсивність фіброзування печінки у хворих на неалкогольний стеатогепатит за коморбідності з хронічною хворобою нирок. Сучасна гастроентерологія. 2017;5(97):29–35.

Abdel-Hamid N.M., Abass S.A., Mohamed A.A. et al. Herbal management of hepatocellular carcinoma through cutting the pathways of the common risk factors. Biomed Pharmacother. 2018;107:1246–1258. doi: 10.1016/j.biopha.2018.08.104.

Ashfaq U.A, Masoud M.S. Nawaz Z., Riazuddin S. Glycyrrhizin as antiviral agent against Hepatitis C Virus. J Transl Med. 2011;9:112. doi: 10.1186/1479-5876-9-112.

Baillya C., Vergotenb G. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? Pharmacol Ther. 2020;214:107618. doi: 10.1016/j.pharmthera.2020.107618.

Choudhry N., Zhao X., Xu D. et al. Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). J Med Chem. 2020;63(22):13205–13227. doi: 10.1021/acs.jmedchem.0c00626.

Chrzanowski J., Chrzanowska A., Wojciech G. Glycyrrhizin: An old weapon against a novel coronavirus. Phytotherapy Research. 2020;1–8. https://doi.org/10.1002/ptr.6852.

Cai X., Wang X., Li J., Chen S. Protective effect of glycyrrhizin on myocardial ischemia/reperfusion injury-induced oxidative stress, inducible nitric oxide synthase and inflammatory reactions through high-mobility group box 1 and mitogen-activated protein kinase expression. Exp Ther Med. 2017 Aug; 14(2): 1219–1226.doi: 10.3892/etm.2017.4617

Czaja A.J. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J. Gastroenterol. 2014;20:2515–2532. doi: 10.3748/wjg.v20.i10.2515.

Eu C.Н.А., Lim W.Y.A., Ton S.H., Kadir K. bin A. Glycyrrhizic acid improved lipoprotein lipase expression, insulin sensitivity, serum lipid and lipid deposition in high-fat diet-induced obese rats. Lipids Health Dis. 2010;9:81. doi: 10.1186/1476-511X-9-81

Fiore C., Eisenhut M., Krausse R. et al. A history of the therapeutic use of liquorice in Europe. J Ethnopharmacol. 2005;99(3):317–24. doi: 10.1016/j.jep.2005.04.015.

Fiore C., Eisenhut M., Ragazzi E. et al. Antiviral effects of Glycyrrhiza species. Phytother Res. 2008;22(2):141–148. doi: 10.1002/ptr.2295.

Haleagrahara N., Varkkey J., Chakravarthi S. Cardioprotective Effects of Glycyrrhizic Acid Against Isoproterenol-Induced Myocardial Ischemia in Rats. Int J Mol Sci. 2011; 12(10): 7100–7113. doi: 10.3390/ijms12107100.

Huang F., Li Y., Leung E.L.-H. et al. A review of therapeutic agents and Chinese herbal medicines against SARSCOV-2 (COVID-19). Pharmacol Res. 2020;158: 104929. doi: 10.1016/j.phrs.2020.104929.

Isbruc R.A., Burdock G.A. Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regul Toxicol Pharmacol. 2006;46(3):167–92. doi: 10.1016/j.yrtph.2006.06.002.

Kleiner D.E., Brunt E.M., Van Natta M. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321. doi: 10.1002/hep.20701.

Li J.-Y., Cao H.-yan, Liu P. et al. Glycyrrhizic Acid in the Treatment of Liver Diseases: Literature Review. Biomed Res Int. 2014;2014:872139. doi: 10.1155/2014/872139.

Liang B., Guo X.-L., Jin J. et al. Glycyrrhizic acid inhibits apoptosis and fibrosis in carbon-tetrachloride-induced rat liver injury. World J Gastroenterol. 2015;21(17):5271–5280. doi: 10.3748/wjg.v21.i17.5271.

Lim W.Y.A., Yin C.Y., Liong S.Y. et al. Lipoprotein lipase expression, serum lipid and tissue lipid deposition in orally-administered glycyrrhizic acid-treated rats. Lipids Health Dis. 2009;8:31. doi: 10.1186/1476-511X-8-31.

Matsui S., Matsumoto H., Sonoda Y. et al. Glycyrrhizin and related compounds down-regulate production of inflammatory chemokines IL-8 and eotaxin 1 in a human lung fibroblast cell line. International munopharmacology. 2004;4(13):1633–1644.

Matsumoto Y. Matsuura T., Aoyagiet H. et al. Antiviral Activity of Glycyrrhizin against Hepatitis C Virus In Vitro. PLoS One. 2013;8(7):e68992. doi: 10.1371/journal.pone.0068992.

Merillon J.-M. and Ramawat G.K. The Pharmacological Activities of Glycyrrhizinic Acid (“Glycyrrhizin”) and Glycyrrhetinic Acid. Sweeteners. 2018:245–261. doi: 10.1007/978-3-319-27027-2_15.

Nakamoto N., Kanai T. Role of toll-like receptors in immune activation and tolerance in the liver. Front. Immunol. 2014;5 doi: 10.3389/fimmu.2014.00221.

Ojha S.K., Sharma C., Golechha M.J. et al. Licorice treatment prevents oxidative stress, restores cardiac function, and salvages myocardium in rat model of myocardial injury. Toxicol. Ind. Health. 2015;31:140–152. doi: 10.1177/0748233713491800.

Öztürk M., Altay V., Hakeem K.R., Akçiçek E. Pharmacological Activities and Phytochemical Constituents Liquorice. 2017:45–72. doi: 10.1007/978-3-319-74240-3_7.

Park H.-Y., Park S.-H., Yoon H.-K., Myung J.H., Kim D.-H. Anti-allergic activity of 18β-glycyrrhetinic acid-3-O-β-D-glucuronide. Archives of Pharmacal Research. 2004;27(1):57–60.

Pastorino G., Cornara L., Soares S. et al. Liquorice (Glycyrrhiza glabra): A phytochemical and pharmacological review. Phytother Res. 2018;32(12):2323–2339. doi: 10.1002/ptr.6178.

Peng C., Stewart A.G., Woodmanet O.L. et al. Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. Front Pharmacol. 2020;11:603926. doi: 10.3389/fphar.2020.603926.

Rockey D.C. Current and Future Antifibrotic Therapies for Chronic Liver Disease. Clin Liver Dis. 2008;12(4):939–xi. doi: 10.1016/j.cld.2008.07.011.

Selyutina O.Yu., Polyakov N.E. Glycyrrhizic acid as a multifunctional drug carrier – From physicochemical properties to biomedical applications: A modern insight on the ancient drug. Int J Pharm. 2019;559:271–279. doi: 10.1016/j.ijpharm.2019.01.047.

Sinha S.K., Prasad S.K., Islam Md A. Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study. J Biomol Struct Dyn. 2020:1–15. doi: 10.1080/07391102.2020.1779132.

Tang Q., Cao Y., Xiong W. et al. Glycyrrhizic acid exerts protective effects against hypoxia/reoxygenation-induced human coronary artery endothelial cell damage by regulating mitochondria. Exp Ther Med. 2020; 20(1): 335–342. doi: 10.3892/etm.2020.8668.

Tsuchida T., Lee Y.A., Fujiwara N. et al. A simple diet– and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J. Hepatol. 2018;69: 385–395. doi: 10.1016/j.jhep.2018.03.011.

Wang H., Fang Z.-Z., Meng R. et al. Glycyrrhizin and glycyrrhetinic acid inhibits alpha-naphthyl isothiocyanate-induced liver injury and bile acid cycle disruption. Toxicology. 2017; 386:133–142. doi: 10.1016/j.tox.2017.05.012.

Wang Q.-S., Gao L.-N, Zhu X.-N. et al. Co-delivery of glycyrrhizin and doxorubicin by alginate nanogel particles attenuates the activation of macrophage and enhances the therapeutic efficacy for hepatocellular carcinoma. Theranostics. 2019;9(21):6239–6255. doi: 10.7150/thno.35972.

Wu H.-J., Yang J.-Y., Jinb M. et al. Glycyrrhetinic Acid Protects the Heart from Ischemia/Reperfusion Injury by Attenuating the Susceptibility and Incidence of Fatal Ventricular Arrhythmia During the Reperfusion Period in the Rat Hearts. Cell Physiol Biochem 2015;36:741–752. doi: 10.1159/000430134.

Xu Y., Guo W., Zhang C. et al. Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application. Front Pharmacol. 2020; 11:601. doi: 10.3389/fphar.2020.00601.

Yan T., Hong W., Cao L. et al. Glycyrrhizin Alleviates Nonalcoholic Steatohepatitis via Modulating Bile Acids and Meta-Inflammation. Drug Metab Dispos. 2018;46(9):1310–1319. doi: 10.1124/dmd.118.082008.

Yang J.D., Hainaut P., Gores G.J. et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi: 10.1038/s41575-019-0186-y.

Yu S., Zhu Y., Xu J. et al. Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2. Phytomedicine. 2020:153364. doi: 10.1016/j.phymed.2020.153364.

Zhai C.-L., Zhang M., Zhang Y. et al. Glycyrrhizin protects rat heart against ischemia-reperfusion injury through blockade of HMGB1-dependent phospho-JNK/Bax pathway. Acta Pharmacol Sin. 2012; 33(12): 1477–1487. doi: 10.1038/aps.2012.112.

Zhang X., Yang H., Yue S. et al. The mTOR inhibition in concurrence with ERK1/2 activation is involved in excessive autophagy induced by glycyrrhizin in hepatocellular carcinoma. Cancer Med. 2017;6(8):1941–1951. doi: 10.1002/cam4.1127.